Tarsus Pharmaceuticals, Inc.: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Paradigm Biocapital Advisors LP amended its Schedule 13G filing on Tarsus Pharmaceuticals, disclosing a change in its beneficial ownership stake under SEC accession 0001104659-26-128301. The filing updates the investment firm's position in the biopharmaceutical company, though the amended document did not specify the exact size of the stake or the direction of the change. Schedule 13G amendments are typically filed by institutional investors when their ownership crosses or adjusts relative to the 5% threshold, making the disclosure a signal of shifting institutional interest in Tarsus. Investors will watch for further 13G or 13D filings to confirm whether Paradigm is building or trimming its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Tarsus Pharmaceuticals, Inc., Paradigm Biocapital Advisors LP